Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME) announced its participation in several upcoming investor conferences. Key events include:

• Citi’s 17th Annual BioPharma Conference on September 7 in Boston, MA.
• Wells Fargo Healthcare Conference on September 8 in Boston, MA.
• Morgan Stanley 20th Annual Global Healthcare Conference on September 13-14 in New York, NY.
• H.C. Wainwright 24th Annual Global Investment Conference with a pre-recorded presentation available on September 12.

The presentations will be accessible on Zymeworks’ website.

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

• Citi’s 17^th Annual BioPharma Conference. Zymeworks will participate in one-on-one meetings and management will participate in a fireside chat on September 7^th in Boston, MA.
• 2022 Wells Fargo Healthcare Conference. Zymeworks will participate in one-on-one meetings and management will participate in a fireside chat on September 8^th in Boston, MA.
• Morgan Stanley 20^th Annual Global Healthcare Conference. Zymeworks will participate in one-on-one meetings on September 13^th and 14^th in New York, NY.
• H.C. Wainwright 24^th Annual Global Investment Conference. Zymeworks will virtually participate in one-on-one meetings on September 13^th and 14^th and will make available a pre-recorded presentation on September 12^th.

The presentation and fireside chats will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005087/en/

Investor Inquiries:

Jack Spinks

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

What events is Zymeworks participating in September 2022?

Zymeworks will participate in the Citi BioPharma Conference on September 7, the Wells Fargo Healthcare Conference on September 8, the Morgan Stanley Global Healthcare Conference on September 13-14, and the H.C. Wainwright Global Investment Conference with a presentation on September 12.

Where can I access Zymeworks' conference presentations?

The presentations and fireside chats will be available on Zymeworks’ website.

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, a bispecific antibody targeting HER2, currently in multiple clinical trials.

What is the focus of Zymeworks' pipeline?

Zymeworks is focused on developing next-generation multifunctional biotherapeutics, primarily in oncology and immuno-oncology.